Fig. S3. Viability of ATDC5 cells treated with various concentrations of hyaluronate (HA), alginate (AL) and hyaluronate-alginate hybrid (HAH) solutions ([ATDC5] = 1×104 cells/well, 24 h). Table S1. Quantified amount of peptide bound to hyaluronate-alginate hybrid. Peptide/alginate HAV/alginate b) RGD/alginate b) a) % Conjugation % Conjugation (mol/g) (mol/g) (mol/g) 5.25 3.7 70 4.4 84 10.5 9.6 91 9.4 89 21 18.3 87 17.4 83 42 33.0 81 38.0 90 105 83.3 79 81.2 77 a) The amount of peptide used to prepare peptide-modified hyaluronate-alginate hybrid. a) The amount of peptide bound to peptide-modified hyaluronate-alginate hybrid.
Fig. S3. Viability of ATDC5 cells treated with various concentrations of hyaluronate (HA), alginate (AL) and hyaluronate-alginate hybrid (HAH) solutions ([ATDC5] = 1×104 cells/well, 24 h). Table S1. Quantified amount of peptide bound to hyaluronate-alginate hybrid. Peptide/alginate a) (mol/g) HAV/alginate b) (mol/g) % Conjugation RGD/alginate b) (mol/g) % Conjugation 5.25 3.7 70 4.4 84 10.5 9.6 91 9.4 89 21 18.3 87 17.4 83 42 33.0 81 38.0 90 105 83.3 79 81.2 77 a) The amount of peptide used to prepare peptide-modified hyaluronate-alginate hybrid. a) The amount of peptide bound to peptide-modified hyaluronate-alginate hybrid.
1-s2.0-S0144861718306702-mmc1.docx